Literature DB >> 34145094

Role of microbial dysbiosis in carcinogenesis & cancer therapies.

Joseph Vimal1, Iris Himal1, S Kannan1.   

Abstract

The human body supports a heterogeneous population of microorganisms. Every microorganism has the ability to contribute to the unique microenvironment around it. The aim of this review is to discuss the changes in the microbial population and their relative abundance across different ecosystems of the human body, the interactions within the microbial communities, metabolites they secrete to their external environment, their immunomodulatory functions, their signal transduction pathways and how these respond to environmental stimuli such as various diets, alcohol and drug consumption, smoking and finally suggest new therapeutic approaches. The microbiota may leads to cancer through inflammation mediated mechanisms which modulate immune responses, or produce carcinogenic metabolites and genotoxins, or deregulate cell proliferative signalling pathways. The identification of these molecular mechanisms in carcinogenesis may lead to better treatment strategies. In this review we have tried to explore the changes in microbial composition between cancer and normal tissues and what molecular mechanisms provide a connecting link between microbial dysbiosis and cancer.

Entities:  

Keywords:  Cancer therapies; carcinogenesis; dysbiosis; immunomodulation; microbiome

Year:  2020        PMID: 34145094     DOI: 10.4103/ijmr.IJMR_1026_18

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  3 in total

1.  The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs).

Authors:  Amr Mohamed; Sylvia L Asa; Thomas McCormick; Hilmi Al-Shakhshir; Arvind Dasari; Retuerto Mauricio; Iman Salem; Lee M Ocuin; David Bajor; Richard T Lee; J Eva Selfridge; Arash Kardan; Zhenghong Lee; Norbert Avril; Shelby Kopp; Jordan M Winter; Jeffrey M Hardacre; John B Ammori; Mahmoud A Ghannoum
Journal:  Curr Issues Mol Biol       Date:  2022-04-30       Impact factor: 2.976

Review 2.  Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances.

Authors:  Hao Qin; Baowen Yuan; Wei Huang; Yan Wang
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

Review 3.  Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine.

Authors:  Oscar Fraile-Martinez; Miguel A Alvarez-Mon; Cielo Garcia-Montero; Leonel Pekarek; Luis G Guijarro; Guillermo Lahera; Miguel A Saez; Jorge Monserrat; Domitila Motogo; Javier Quintero; Melchor Alvarez-Mon; Miguel A Ortega
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.